- Advertisement -
BY THE OPTIMIST DAILY EDITORIAL TEAM
In a 500-patient trial at American Society of Clinical Oncology’s (ASCO) annual meeting in Chicago, a daily pill called daraxonrasib doubled average survival time in patients with advanced pancreatic cancer. Those on the drug lived for an average of 13.2…
